E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 3/17/2009 in the Prospect News Investment Grade Daily.

New Issue: Pfizer prices $13.5 billion of notes in five tranches

By Andrea Heisinger

New York, March 17 - Pfizer Inc. priced $13.5 billion of notes (Aa2/AAA/AA) in five tranches Tuesday, a day after the deal was announced, an informed source said.

A term sheet was not available at press time.

A $1.25 billion tranche of two-year floating-rate notes priced at par with a coupon of three-month Libor plus 195 basis points. This was at the tight end of guidance of Libor plus 200 bps, plus or minus 5 bps.

The $3.5 billion of 4.45% three-year notes priced to yield Treasuries plus 305 bps. Guidance was in the 310 bps area.

The $3 billion of 5.35% six-year notes priced to yield Treasuries plus 340 bps, making it also at the tight end of price talk that was in the 345 bps area.

The $3.25 billion of 6.2% 10-year notes priced to yield Treasuries plus 325 bps. Price talk was in the 330 bps area.

The $2.5 billion final tranche of 7.2% 30-year notes priced to yield Treasuries plus 345 bps. Like the other tranches, this was at the tight end of talk that was in the 350 bps area.

Price talk for all of the tranches had a margin of plus or minus 5 bps.

Bookrunners were Banc of America Securities LLC, Barclays Capital Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. and J.P. Morgan Securities Inc.

Co-managers were Credit Suisse Securities, Deutsche Bank Securities Inc., RBS Greenwich Capital, HSBC Securities, Mitsubishi UFJ Securities, Santander Investment and UBS Investment Bank.

Proceeds will be used for general corporate purposes, including funding a portion of the purchase price of the Wyeth acquisition and refinancing existing debt. The proceeds may also be temporarily invested in short-term marketable securities.

The pharmaceutical company is based in New York City.

Issuer:Pfizer Inc.
Issue:Notes
Total amount:$13.5 billion
Bookrunners:Banc of America Securities LLC, Barclays Capital Inc., Citigroup Global Markets Inc., Goldman Sachs & Co., J.P. Morgan Securities Inc.
Co-managers:Credit Suisse Securities, Deutsche Bank Securities Inc., RBS Greenwich Capital, HSBC Securities, Mitsubishi UFJ Securities, Santander Investment, UBS Investment Bank
Trade date:March 17
Settlement date:March 24
Ratings:Moody's: Aa2
Standard & Poor's: AAA
Fitch: AA
Two-year floaters
Amount:$1.25 billion
Maturity:March 15, 2011
Coupon:Three-month Libor plus 195 bps
Price:Par
Yield:Three-month Libor plus 195 bps
Price talk:Three-month Libor plus 200 bps, plus or minus 5 bps
Three-year notes
Amount:$3.5 billion
Maturity:March 15, 2012
Coupon:4.45%
Spread:Treasuries plus 305 bps
Price talk:310 bps area, plus or minus 5 bps
Six-year notes
Amount:$3 billion
Maturity:March 15, 2015
Coupon:5.35%
Spread:Treasuries plus 340 bps
Price talk:345 bps area, plus or minus 5 bps
10-year notes
Amount:$3.25 billion
Maturity:March 15, 2019
Coupon:6.2%
Spread:Treasuries plus 325 bps
Price talk:330 bps, plus or minus 5 bps
30-year notes
Amount:$2.5 billion
Maturity:March 15, 2039
Coupon:7.2%
Spread:Treasuries plus 345 bps
Price talk:350 bps area, plus or minus 5 bps

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.